Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad694 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Yoshitomo Hoshino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, 105-8470, Japan. Hauptthemen laut MEDLINE: Diabetes Insipidus, Neurogenic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Okinaka Memorial Institute for Medical Research, JSPS.
Abstract (Originalsprache)
Context
Desmopressin orally disintegrating tablets (ODTs) are widely used to treat arginine vasopressin deficiency (AVP-D). However, limited information is available on the dosage regimen; the dosage for each patient is selected based on their response to the initiation dose.
Objective
To investigate the relationships between clinical characteristics and the daily dose of ODTs and to identify factors that affect ODT dosages.
Methods
This retrospective study included 209 adult patients with AVP-D. Patients were administered ODTs sublingually and instructed to restrict eating and drinking for 30 minutes after taking ODTs using a patient leaflet. ODT dose titration was conducted during hospitalization with close monitoring of urine output, body weight, and serum sodium levels. Multivariable linear regression models were applied to identify clinical factors associated with the daily dose of ODTs at discharge. We also evaluated the dosage at 1 year in 134 patients who were followed up in our hospital.
Results
The median daily dose of ODTs at discharge was 90 µg (IQR 60-120 µg). Multivariable linear regression models identified sex, age, and estimated creatinine clearance (eCCr) as significant factors associated with the daily dose of ODTs, with eCCr having the strongest effect. After excluding patients recovering from AVP-D, 71% of those followed up at our hospital took the same daily dose at 1 year after discharge.
Conclusion
To achieve the safe and stable treatment of AVP-D, the daily dose of ODT needs to be selected based on a patient's sex, age, and eCCr under appropriate sublingual administration by patient education.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, 105-8470, Japan.
- Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, 113-8655, Japan.
- Department of Social Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8501, Japan.
- Hakubi Center, Kyoto University, Kyoto, 606-8501, Japan.
- Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, 105-8470, Japan.
- Okinaka Memorial Institute for Medical Research, Tokyo, 105-8470, Japan.
ORCID-Profile: Yoshitomo Hoshino, Kosuke Inoue, Hiroshi Nishioka, Akira Takeshita
Förderung
- Okinaka Memorial Institute for Medical Research
- JSPS
Zitieren
APA
Hoshino, Y., Inoue, K., Ikeda, S., Goshima, Y., Tatsushima, K., Fukuhara, N., Okada, M., Nishioka, H., Yamada, S., Takeuchi, Y., & Takeshita, A. (2024). Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad694
Vancouver
Hoshino Y, Inoue K, Ikeda S, Goshima Y, Tatsushima K, Fukuhara N, et al. Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad694
BibTeX
@article{Hoshino2024,
author = {Hoshino, Yoshitomo and Inoue, Kosuke and Ikeda, Sara and Goshima, Yukiko and Tatsushima, Keita and Fukuhara, Noriaki and Okada, Mitsuo and Nishioka, Hiroshi and Yamada, Shozo and Takeuchi, Yasuhiro and Takeshita, Akira},
title = {Clinical Factors Affecting Daily Dosage of Desmopressin Orally Disintegrating Tablets in Arginine Vasopressin Deficiency},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad694}
}
EUVIMED